Tri-Specific Antibody IBI3003 Enters Phase 3 for Relapsed Multiple Myeloma
Innovent's IBI3003 targets three cancer proteins at once, showing 83% response rates in early trials for hard-to-treat blood cancer.
Summary
Innovent Biologics has launched a major Phase 3 trial testing IBI3003, a novel tri-specific antibody for relapsed or refractory multiple myeloma — a blood cancer that becomes increasingly difficult to treat after prior therapies. Unlike existing bispecific antibodies that target one cancer marker, IBI3003 simultaneously targets GPRC5D, BCMA, and CD3, potentially improving cancer cell elimination. Early-phase data presented at a top hematology conference in December 2025 showed an 83.3% overall response rate in patients receiving higher doses, with mostly mild side effects. The drug has also received FDA Fast Track designation, accelerating its potential path to approval. This trial compares IBI3003 against established drug combinations in second- to fifth-line treatment settings, with progression-free survival as the key success measure.
Detailed Summary
Multiple myeloma is a cancer of plasma cells in the bone marrow, and while treatments have advanced significantly, most patients eventually relapse and face shrinking options. Innovent Biologics is now testing IBI3003, a tri-specific antibody, in a registrational Phase 3 trial — a meaningful step toward a potential new standard of care for patients who have failed prior therapies.
IBI3003 works by simultaneously binding three targets: GPRC5D and BCMA on myeloma cells, and CD3 on immune T-cells. This triple engagement is designed to physically bridge immune cells to cancer cells, triggering destruction of the tumor with potentially greater precision and potency than existing bispecific antibodies that target only one tumor antigen.
Early clinical data presented at the American Society of Hematology meeting in December 2025 were encouraging. Among 24 patients receiving doses at or above 120 μg/kg, the overall response rate reached 83.3%. Side effects, including cytokine release syndrome — a common immune reaction with this class of drugs — were predominantly mild to moderate and described as manageable.
The Phase 3 trial, TriadicMM-1, is a multicenter, randomized, controlled study based in China comparing IBI3003 against two established chemotherapy combinations: pomalidomide-bortezomib-dexamethasone or daratumumab-pomalidomide-dexamethasone. Progression-free survival, assessed by an independent committee, is the primary endpoint — a rigorous measure that regulators take seriously.
For health-conscious readers, this development signals rapid progress in immunotherapy for blood cancers. While myeloma is not preventable through lifestyle alone, the emergence of tri-specific antibodies represents a broader shift toward precision immune therapies that could eventually influence treatment across multiple cancer types. The FDA Fast Track designation suggests U.S. regulators see meaningful potential here, though full approval awaits Phase 3 results.
Key Findings
- IBI3003 achieved an 83.3% overall response rate at doses ≥120 μg/kg in early-phase myeloma patients.
- The drug targets three proteins simultaneously — GPRC5D, BCMA, and CD3 — unlike existing bispecific antibodies.
- Phase 3 trial compares IBI3003 to two established drug regimens in relapsed or refractory myeloma patients.
- Cytokine release syndrome side effects were mostly Grade 1–2, suggesting a manageable safety profile so far.
- FDA granted IBI3003 Fast Track designation, potentially accelerating its path to U.S. approval.
Methodology
This is a news report summarizing a clinical trial initiation and early-phase data from Innovent Biologics' press communications and an ASH 2025 conference presentation. The source, Longevity.Technology, is a science-focused outlet; claims originate from the company and have not yet been independently peer-reviewed in full. Evidence basis is early-phase clinical data (Phase 1/2), which carries inherent limitations before Phase 3 confirmation.
Study Limitations
Early-phase response rate data (n=24) is preliminary and from a non-randomized cohort; Phase 3 results are required for confirmatory evidence. The trial is conducted primarily in China, which may affect generalizability to Western populations. Long-term survival outcomes, durability of response, and full safety profiles remain unknown pending trial completion.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: